Reuters logo
Momenta's Humira biosimilar succeeds in key psoriasis study
November 29, 2016 / 1:22 PM / in a year

Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 (Reuters) - U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc’s top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

As it is not possible to produce exact copies of biotech drugs made from living cells, the cheaper versions - referred to as biosimilars rather than generics - are intended to save costs compared to more expensive biologic medicines.

Humira, considered the world’s biggest-selling medicine, generates $15 billion in annual sales and treats rheumatoid arthritis, Crohn’s disease and psoriasis. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below